Zobrazeno 1 - 10
of 84
pro vyhledávání: '"David A. DeMicco"'
Autor:
Liffert Vogt, Sripal Bangalore, Rana Fayyad, Shari Melamed, G. Kees Hovingh, David A. DeMicco, David D. Waters
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 8, Iss 9 (2019)
Background Kidney function decreases during the lifetime, and this decline is a powerful predictor of both kidney and cardiovascular outcomes. Statins lower cardiovascular risk, which may relate to beneficial effects on kidney function. We studied wh
Externí odkaz:
https://doaj.org/article/0257b1f7ed234bc98c40d14792a31da0
Autor:
Kwok Leung Ong, David D. Waters, Rana Fayyad, Liffert Vogt, Shari Melamed, David A. DeMicco, Kerry‐Anne Rye, Philip J. Barter
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 7, Iss 2 (2018)
BackgroundIt is not known whether the concentration of high‐density lipoprotein (HDL) cholesterol is related to renal function in statin‐treated patients. We therefore investigated whether HDL cholesterol levels predicted renal function in atorva
Externí odkaz:
https://doaj.org/article/5c8ebde304f845a9bde6ace2d166c688
Autor:
Philip J. Barter, Kerry-Anne Rye, Mohan S. Beltangady, William C. Ports, William T. Duggan, S. Matthijs Boekholdt, David A. DeMicco, John J.P. Kastelein, Charles L. Shear
Publikováno v:
Journal of Lipid Research, Vol 53, Iss 11, Pp 2436-2442 (2012)
Development of the cholesteryl ester transfer protein (CETP) inhibitor, torcetrapib, was halted after the ILLUMINATE trial revealed an increase in both all-cause mortality (ACM) and major cardiovascular events (MCVEs) associated with its use. We now
Externí odkaz:
https://doaj.org/article/189e656ae8a649159ae60d68943931b9
Autor:
Harshal A. Deshmukh, Helen M. Colhoun, Toby Johnson, Paul M. McKeigue, D. John Betteridge, Paul N. Durrington, John H. Fuller, Shona Livingstone, Valentine Charlton-Menys, Andrew Neil, Neil Poulter, Peter Sever, Denis C. Shields, Alice V. Stanton, Aurobindo Chatterjee, Craig Hyde, Roberto A. Calle, David A. DeMicco, Stella Trompet, Iris Postmus, Ian Ford, J. Wouter Jukema, Mark Caulfield, Graham A. Hitman
Publikováno v:
Journal of Lipid Research, Vol 53, Iss 5, Pp 1000-1011 (2012)
We carried out a genome-wide association study (GWAS) of LDL-c response to statin using data from participants in the Collaborative Atorvastatin Diabetes Study (CARDS; n = 1,156), the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT; n = 895), and th
Externí odkaz:
https://doaj.org/article/0e30b62ae4ad49fe9ad70c633f99fac3
Autor:
Michael Szarek, Rana Fayyad, Rachel Laskey, Larry B. Goldstein, Investigators, Henrik Sillesen, Pierre Amarenco, Alfred Callahan, K. Michael A. Welch, Sparcl Committees, David A. DeMicco
Publikováno v:
Journal of the American College of Cardiology. 75:2110-2118
Background In the SPARCL (Stroke Prevention by Aggressive Reduction in Cholesterol Levels) trial, atorvastatin was compared with placebo in 4,731 participants with recent stroke or transient ischemic attack and no known coronary heart disease. Atorva
Autor:
Benoit J Arsenault, Philip Barter, David A DeMicco, Weihang Bao, Gregory M Preston, John C LaRosa, Scott M Grundy, Prakash Deedwania, Heiner Greten, Nanette K Wenger, James Shepherd, David D Waters, John J P Kastelein, Treating to New Targets (TNT) Investigators
Publikováno v:
PLoS ONE, Vol 9, Iss 12, p e114519 (2014)
Several plasma non-lipid biomarkers have been shown to predict major cardiovascular events (MCVEs) in population studies. Our objective was to investigate the relationship between lipid and non-lipid biomarkers levels achieved during statin therapy a
Externí odkaz:
https://doaj.org/article/9b5a5887723d480fad24e9e88d562e78
Autor:
Rana Fayyad, John J.P. Kastelein, David D. Waters, Sripal Bangalore, Franz H. Messerli, Rachel Laskey, David A. DeMicco
Publikováno v:
American journal of cardiology, 119(3), 379-387. Elsevier Inc.
In patients with previous myocardial infarction (MI), aggressive hypertension control and low-density lipoprotein cholesterol (LDL-C) reduction are important secondary prevention measures. However, residual risk remains despite aggressive treatment.
Autor:
Nicholas Hui, Rana Fayyad, Nadeem O. Kaakoush, Philip J. Barter, Alicia J. Jenkins, Andrzej S. Januszewski, Kerry-Anne Rye, Anthony C Keech, Kwok Leung Ong, Aimin Xu, David A. DeMicco, David D. Waters
Publikováno v:
Ong, Kwok Leung; Hui, Nicholas; Januszewski, Andrzej S; Kaakoush, Nadeem O; Xu, Aimin; Fayyad, Rana; et al.(2019). High plasma FGF21 levels predicts major cardiovascular events in patients treated with atorvastatin (from the Treating to New Targets [TNT] Study).. Metabolism: clinical and experimental, 93, 93-99. doi: 10.1016/j.metabol.2018.11.006. UCSF: Retrieved from: http://www.escholarship.org/uc/item/2w12n51r
Background Higher plasma fibroblast growth factor 21 (FGF21) levels predict incident cardiovascular events in type 2 diabetes patients. However, whether FGF21 levels predict cardiovascular events in statin-treated patients in the general population i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0dc345bc88289bfa9302c81101dd39ba
https://escholarship.org/uc/item/2w12n51r
https://escholarship.org/uc/item/2w12n51r
Publikováno v:
Circulation. Cardiovascular quality and outcomes, vol 11, iss 11
Bangalore, S, Fayyad, R, DeMicco, D A, Colhoun, H M & Waters, D D 2018, ' Body Weight Variability and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus ', Circulation: Cardiovascular Quality and Outcomes, vol. 11, no. 11, pp. e004724 . https://doi.org/10.1161/CIRCOUTCOMES.118.004724
Bangalore, S, Fayyad, R, DeMicco, D A, Colhoun, H M & Waters, D D 2018, ' Body Weight Variability and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus ', Circulation: Cardiovascular Quality and Outcomes, vol. 11, no. 11, pp. e004724 . https://doi.org/10.1161/CIRCOUTCOMES.118.004724
Background: Some studies have shown that body weight variability is a risk factor for cardiovascular events, but this has not been studied in subjects with diabetes mellitus. Methods and Results: We measured intraindividual variations in body weight
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06188b42cdc970c68c27360b1253ee52
https://escholarship.org/uc/item/1r61q4x0
https://escholarship.org/uc/item/1r61q4x0
Autor:
David A. DeMicco, Sripal Bangalore, John J.P. Kastelein, Rachel Laskey, Rana Fayyad, David D. Waters, Pierre Amarenco
Publikováno v:
American journal of medicine, 129(4), 384-391. Elsevier Inc.
The 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guideline on the treatment of blood cholesterol recommends moderate- to high-intensity statins for patients with atherosclerotic cardiovascular disease but departs from th